Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During ...
November 20 2020 - 7:30AM
Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell
therapy to treat cancer, will host a virtual Investor Day today,
which will feature the Company’s Senior Leadership team and Dr
Dejka Araujo of the MD Anderson Cancer Center. The link to register
is HERE and further background information on Adaptimmune and the
event can be found HERE. After the event, a copy of the
presentation materials and webcast links will be posted on the
Events and Presentations page under the Investors section of the
Adaptimmune website.
“We will lay out the strategy confirming our leadership position
as a company designing and delivering cell therapies for people
with cancer,” said Adrian Rawcliffe, Adaptimmune’s Chief Executive
Officer. “Over the next five years, we plan to deliver two marketed
products, one in sarcoma and one in gastroesophageal cancers, and
two additional BLAs in other solid tumor indications. We also plan
to develop a robust autologous and allogeneic clinical pipeline
that takes us towards the ultimate goal of curative and mainstream
cell therapies for people with cancer.”
Adaptimmune’s Virtual Investor Day will cover the following
topics:
Opening Remarks by Adrian Rawcliffe, CEO
- Strategic vision for Adaptimmune and core value drivers for the
next five years
- Delivering TCR T-cell therapies and building the cell therapy
company of the future
- MAGE-A4 is a target with large market potential across a broad
range of solid tumor indications including synovial sarcoma, lung,
head and neck, bladder, and gastroesophageal cancers
Synovial sarcoma care: the need for cell
therapy
- Dejka Araujo, M.D. (Professor in the Department of Sarcoma
Medical Oncology, Division of Cancer Medicine of the MD Anderson
Cancer Center) will discuss the current treatment landscape and
unmet medical need for people with synovial sarcoma
Driving towards delivery of two marketed
products and two further BLAs by
2025
- An overview of plans to launch the first TCR T-cell therapy
(ADP-A2M4) in synovial sarcoma as enrollment in the SPEARHEAD-1
trial is on track
- Plan to file a BLA with ADP-A2M4D8 in gastroesophageal cancers
in 2024
- Potential addressable population across all tumor types with
significant MAGE-A4 expression of ~39,000 patients per year in the
US and EU factored for HLA-A21; additional BLA(s) projected with
ADP-A2M4CD8 in tumor types beyond gastroesophageal cancers
- Additional BLA projected for ADP-A2AFP (first or
next-generation CD8α) with a potential market opportunity of
~16,000 patients per year based on serum AFP expression1 and
factoring for HLA-A2
- Plan to incorporate next-generation CD8α enhancement into SPEAR
T-cells targeting AFP in a clinical trial next year
The importance of building an
integrated cell therapy company for rapid
execution and success
- An overview of the Company’s integrated structure with its
leading capabilities for designing and delivering cell
therapies
- Case studies demonstrating the value that this integrated
approach has delivered: rapid execution of clinical programs,
security of vector supply, reduction of costs, and learnings
applied to the allogeneic platform
A rich cell therapy pipeline for the future
over the next 5 years
- Focusing on curative intent: leveraging translational insights
for best next-generation products:
- Positioning multiple enhancements for next-generation SPEAR
T-cells including:
- ADP-A2M4 SPEAR T-cells co-expressing IL-7, IL-15, dnTGFβ, and/
or PDE7
- Enhancing SPEAR T-cells with IL-7 for proliferation and
survival and CCL19 for migration into tumor in collaboration with
Noile-Immune
- Enhancing SPEAR T-cells using transmembrane and surface
immunoregulatory mechanisms with Alpine Immune Sciences
- Focusing on enabling mainstream access – broadening patient
coverage and patient access:
- Plans to expand into HLAs beyond A2 to increase the addressable
patient population
- Bringing forward HiT candidates for multiple targets including
GPC3
- Announcing collaboration with leading TIL therapy center (CCIT,
Denmark) for nextgeneration TILs co-expressing IL-7
- Bringing two allogeneic targets into the clinic:
- In-house MAGE A4 targeted iPSC T-cell products
- Mesothelin, a target expressed in multiple solid tumors, named
as first HiT target in partnership with Astellas
An update on the
Company’s financial position
- Total liquidity position of $400 million as of September 30,
2020
- Current cash runway into early 2023
The Virtual Investor Day will also include two Q&A
sessions.
About AdaptimmuneAdaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products for people with cancer. The
Company’s unique SPEAR® (Specific Peptide Enhanced Affinity
Receptor) T-cell platform enables the engineering of T-cells to
target and destroy cancer across multiple solid tumors.
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Quarterly Report on
Form 10-Q filed with the SEC on November 5, 2020, and our other SEC
filings. The forward-looking statements contained in this press
release speak only as of the date the statements were made and we
do not undertake any obligation to update such forward-looking
statements to reflect subsequent events or
circumstances.
Media Relations:
Sébastien Desprez — VP, Communications and Investor RelationsT:
+44 1235 430 583M: +44 7718 453
176Sebastien.Desprez@adaptimmune.com
Investor Relations:
Juli P. Miller, Ph.D. — Senior Director, Investor RelationsT: +1
215 825 9310M: +1 215 460 8920Juli.Miller@adaptimmune.com
________________1 Mortality figures based on American Cancer
Society 2020 (US) and Global Can (EU) – Synovial sarcoma data based
on internal market research; MAGE A4 expression ranges based on
ADAP samples and expression cut-off criteria of ≥30% tumor cells at
≥2+ intensity; HLA-A2 expression of 41% based on ADAP samples
(1,043 patient samples); Serum AFP expression ranges based on
internal samples (62 patients) and expression cut off
>100ng/mL
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Sep 2023 to Sep 2024